Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients.
Aged
Biomarkers
C-Reactive Protein
/ metabolism
COVID-19
Female
Humans
Interleukin-6
Lactate Dehydrogenases
Male
Progranulins
Receptors, Tumor Necrosis Factor, Type I
/ metabolism
Receptors, Tumor Necrosis Factor, Type II
/ metabolism
Renal Insufficiency, Chronic
Retrospective Studies
Severity of Illness Index
Tumor Necrosis Factor-alpha
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
06
2022
accepted:
22
09
2022
entrez:
11
10
2022
pubmed:
12
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
Although hyperinflammatory response influences the severity of coronavirus disease 2019 (COVID-19), little has been reported about the utility of tumor necrosis factor (TNF)-related biomarkers in reflecting the prognosis. We examined whether TNF receptors (TNFRs: TNFR1, TNFR2) and progranulin (PGRN) levels, in addition to interleukin 6 (IL-6) and C-reactive protein (CRP), are associated with mortality or disease severity in COVID-19 patients. This retrospective study was conducted at Juntendo University Hospital. Eighty hospitalized patients with various severities of COVID-19 were enrolled. Furthermore, serum levels of TNF-related biomarkers were measured using enzyme-linked immunosorbent assay. Twenty-five patients died during hospitalization, and 55 were discharged. The median (25th and 75th percentiles) age of the study patients was 70 (61-76) years, 44 (55.0%) patients were males, and 26 (32.5%) patients had chronic kidney disease (CKD). When comparing with patients who received and did not receive treatment at the intensive care unit (ICU), the former had a higher tendency of being male and have diabetes, hypertension, and CKD; had higher levels of white blood cells, D-dimer, and lactate dehydrogenase; and had lower body mass index, estimated glomerular filtration rate, and lymphocyte counts. Significant differences were observed in TNFR, PGRN, IL-6, and CRP levels between each severity (mild-severe) group. Furthermore, the serum levels of TNFR, IL-6, and CRP, but not PGRN, in ICU patients were significantly higher than in the patients who were not admitted to the ICU. Multivariate logistic regression analysis demonstrated that high levels of TNFR2 were only associated with mortality in patients with COVID-19 even after adjustment for relevant clinical parameters. High TNFR2 level might be helpful for predicting mortality or disease severity in patients with COVID-19.
Sections du résumé
BACKGROUND
Although hyperinflammatory response influences the severity of coronavirus disease 2019 (COVID-19), little has been reported about the utility of tumor necrosis factor (TNF)-related biomarkers in reflecting the prognosis. We examined whether TNF receptors (TNFRs: TNFR1, TNFR2) and progranulin (PGRN) levels, in addition to interleukin 6 (IL-6) and C-reactive protein (CRP), are associated with mortality or disease severity in COVID-19 patients.
METHODS
This retrospective study was conducted at Juntendo University Hospital. Eighty hospitalized patients with various severities of COVID-19 were enrolled. Furthermore, serum levels of TNF-related biomarkers were measured using enzyme-linked immunosorbent assay.
RESULTS
Twenty-five patients died during hospitalization, and 55 were discharged. The median (25th and 75th percentiles) age of the study patients was 70 (61-76) years, 44 (55.0%) patients were males, and 26 (32.5%) patients had chronic kidney disease (CKD). When comparing with patients who received and did not receive treatment at the intensive care unit (ICU), the former had a higher tendency of being male and have diabetes, hypertension, and CKD; had higher levels of white blood cells, D-dimer, and lactate dehydrogenase; and had lower body mass index, estimated glomerular filtration rate, and lymphocyte counts. Significant differences were observed in TNFR, PGRN, IL-6, and CRP levels between each severity (mild-severe) group. Furthermore, the serum levels of TNFR, IL-6, and CRP, but not PGRN, in ICU patients were significantly higher than in the patients who were not admitted to the ICU. Multivariate logistic regression analysis demonstrated that high levels of TNFR2 were only associated with mortality in patients with COVID-19 even after adjustment for relevant clinical parameters.
CONCLUSIONS
High TNFR2 level might be helpful for predicting mortality or disease severity in patients with COVID-19.
Identifiants
pubmed: 36219652
doi: 10.1371/journal.pone.0275745
pii: PONE-D-22-16971
pmc: PMC9553057
doi:
Substances chimiques
Biomarkers
0
Interleukin-6
0
Progranulins
0
Receptors, Tumor Necrosis Factor, Type I
0
Receptors, Tumor Necrosis Factor, Type II
0
Tumor Necrosis Factor-alpha
0
C-Reactive Protein
9007-41-4
Lactate Dehydrogenases
EC 1.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0275745Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Med (Lausanne). 2021 Jul 12;8:634932
pubmed: 34322499
Am J Respir Crit Care Med. 2016 Nov 15;194(10):1219-1232
pubmed: 27149013
J Am Soc Nephrol. 2012 Mar;23(3):516-24
pubmed: 22266664
J Epidemiol. 2021 Aug 5;31(8):487-494
pubmed: 34053961
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Front Immunol. 2021 Apr 22;12:592727
pubmed: 33968010
Front Endocrinol (Lausanne). 2022 Apr 01;13:849457
pubmed: 35432201
J Med Virol. 2020 Oct;92(10):1875-1883
pubmed: 32441789
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Int J Mol Sci. 2020 Mar 13;21(6):
pubmed: 32183005
J Diabetes Investig. 2021 Mar;12(3):382-389
pubmed: 32643269
Sci Rep. 2021 Jan 13;11(1):1194
pubmed: 33441916
Am J Physiol Renal Physiol. 2014 Jun 1;306(11):F1335-47
pubmed: 24647715
Int J Mol Sci. 2021 Aug 05;22(16):
pubmed: 34445140
Sci Rep. 2017 Mar 03;7:43520
pubmed: 28256549
Diabetes Care. 2014 May;37(5):1425-31
pubmed: 24623026
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Sci Rep. 2018 Oct 17;8(1):15302
pubmed: 30333553
Curr Diab Rep. 2013 Aug;13(4):560-6
pubmed: 23657763
Lancet Haematol. 2020 Sep;7(9):e671-e678
pubmed: 32659214
Pharmacol Ther. 2012 Jan;133(1):124-32
pubmed: 22008260
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14
pubmed: 18490652
J Infect Dis. 2021 Mar 3;223(5):805-810
pubmed: 33249506
FEBS Open Bio. 2020 Dec;10(12):2761-2770
pubmed: 33098615
Int J Mol Sci. 2021 May 22;22(11):
pubmed: 34067256
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
PLoS One. 2021 Jul 27;16(7):e0255379
pubmed: 34314447
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
J Inflamm Res. 2021 Sep 21;14:4785-4794
pubmed: 34584437
Nat Med. 2019 May;25(5):805-813
pubmed: 31011203
J Am Soc Nephrol. 2012 Mar;23(3):507-15
pubmed: 22266663
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Front Immunol. 2020 Oct 07;11:576745
pubmed: 33117379